BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 26140726)

  • 1. Anthracycline-Induced Cardiomyopathy in Adults.
    Tan TC; Neilan TG; Francis S; Plana JC; Scherrer-Crosbie M
    Compr Physiol; 2015 Jul; 5(3):1517-40. PubMed ID: 26140726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exposure to anthracyclines during childhood causes cardiac injury.
    Lipshultz SE
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anthracycline-related cardiotoxicity in childhood cancer survivors.
    Lipshultz SE; Karnik R; Sambatakos P; Franco VI; Ross SW; Miller TL
    Curr Opin Cardiol; 2014 Jan; 29(1):103-12. PubMed ID: 24284979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Noninvasive early detection of anthracycline-induced cardiotoxicity in patients with hematologic malignancies using the phased tracking method.
    Saito Y; Susukida I; Uzuka Y; Kanai H
    Cancer Med; 2016 Sep; 5(9):2276-85. PubMed ID: 27484957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiotoxicity in anthracycline therapy: Prevention strategies.
    Cruz M; Duarte-Rodrigues J; Campelo M
    Rev Port Cardiol; 2016 Jun; 35(6):359-71. PubMed ID: 27255173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacologic prevention of anthracycline-induced cardiomyopathy.
    Maradia K; Guglin M
    Cardiol Rev; 2009; 17(5):243-52. PubMed ID: 19690476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence, time of occurrence and response to heart failure therapy in patients with anthracycline cardiotoxicity.
    Khan AA; Ashraf A; Singh R; Rahim A; Rostom W; Hussain M; Renner I; Collins NJ
    Intern Med J; 2017 Jan; 47(1):104-109. PubMed ID: 27800661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of anthracycline-induced cardiotoxicity: a systematic review and meta-analysis.
    Caspani F; Tralongo AC; Campiotti L; Asteggiano R; Guasti L; Squizzato A
    Intern Emerg Med; 2021 Mar; 16(2):477-486. PubMed ID: 33011930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidemiology of anthracycline cardiotoxicity in children and adults.
    Grenier MA; Lipshultz SE
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):72-85. PubMed ID: 9768828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anthracycline-induced cardiomyopathy.
    Simmons A; Vacek JL; Meyers D
    Postgrad Med; 2008 Nov; 120(4):67-72. PubMed ID: 19020367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management.
    Iarussi D; Indolfi P; Casale F; Martino V; Di Tullio MT; Calabrò R
    Paediatr Drugs; 2005; 7(2):67-76. PubMed ID: 15871628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardioprotective role of β-blockers and angiotensin antagonists in early-onset anthracyclines-induced cardiotoxicity in adult patients: a systematic review and meta-analysis.
    Yun S; Vincelette ND; Abraham I
    Postgrad Med J; 2015 Nov; 91(1081):627-33. PubMed ID: 26399268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early detection of anthracycline-mediated cardiotoxicity: the value of considering both global longitudinal left ventricular strain and twist.
    Mornoş C; Petrescu L
    Can J Physiol Pharmacol; 2013 Aug; 91(8):601-7. PubMed ID: 23889668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benefits of antihypertensive medications for anthracycline- and trastuzumab-induced cardiotoxicity in patients with breast cancer: Insights from recent clinical trials.
    Rygiel K
    Indian J Pharmacol; 2016; 48(5):490-497. PubMed ID: 27721532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Preventive Role of Angiotensin Converting Enzyme Inhibitors/Angiotensin-II Receptor Blockers and β-Adrenergic Blockers in Anthracycline- and Trastuzumab-Induced Cardiotoxicity.
    Blanter JB; Frishman WH
    Cardiol Rev; 2019; 27(5):256-259. PubMed ID: 31008768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation and management of chemotherapy-induced cardiotoxicity in breast cancer: a Delphi study.
    Gavila J; Seguí MÁ; Calvo L; López T; Alonso JJ; Farto M; Sánchez-de la Rosa R
    Clin Transl Oncol; 2017 Jan; 19(1):91-104. PubMed ID: 27101413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting and Preventing Anthracycline-Related Cardiotoxicity.
    Armenian S; Bhatia S
    Am Soc Clin Oncol Educ Book; 2018 May; 38():3-12. PubMed ID: 30231396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cardiotoxicity of anthracyclines].
    Costache II; Petriş A
    Rev Med Chir Soc Med Nat Iasi; 2011; 115(4):1200-7. PubMed ID: 22276470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer.
    Jensen BV
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S15-21. PubMed ID: 16781285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anthracycline-associated cardiotoxicity in survivors of childhood cancer.
    Trachtenberg BH; Landy DC; Franco VI; Henkel JM; Pearson EJ; Miller TL; Lipshultz SE
    Pediatr Cardiol; 2011 Mar; 32(3):342-53. PubMed ID: 21221562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.